

Modulation of neutrophil extracellular trap and reactive oxygen species release by periodontal bacteria

Hirschfeld, Josefine; White, Phillipa; Milward, Michael; Cooper, Paul; Chapple, Iain

DOI:

[10.1128/IAI.00297-17](https://doi.org/10.1128/IAI.00297-17)

License:

None: All rights reserved

Document Version

Peer reviewed version

Citation for published version (Harvard):

Hirschfeld, J, White, P, Milward, M, Cooper, P & Chapple, I 2017, 'Modulation of neutrophil extracellular trap and reactive oxygen species release by periodontal bacteria', *Infection and Immunity*, vol. 85, no. 12, pp. e00297-17. <https://doi.org/10.1128/IAI.00297-17>

[Link to publication on Research at Birmingham portal](#)

Publisher Rights Statement:

Checked for eligibility: 17/01/2017

Hirschfeld J, White PC, Milward MR, Cooper PR, Chapple ILC. 2017. Modulation of neutrophil extracellular trap and reactive oxygen species release by periodontal bacteria. *Infect Immun* 85:e00297-17. <https://doi.org/10.1128/IAI.00297-17>

General rights

Unless a licence is specified above, all rights (including copyright and moral rights) in this document are retained by the authors and/or the copyright holders. The express permission of the copyright holder must be obtained for any use of this material other than for purposes permitted by law.

- Users may freely distribute the URL that is used to identify this publication.
- Users may download and/or print one copy of the publication from the University of Birmingham research portal for the purpose of private study or non-commercial research.
- User may use extracts from the document in line with the concept of 'fair dealing' under the Copyright, Designs and Patents Act 1988 (?)
- Users may not further distribute the material nor use it for the purposes of commercial gain.

Where a licence is displayed above, please note the terms and conditions of the licence govern your use of this document.

When citing, please reference the published version.

Take down policy

While the University of Birmingham exercises care and attention in making items available there are rare occasions when an item has been uploaded in error or has been deemed to be commercially or otherwise sensitive.

If you believe that this is the case for this document, please contact UBIRA@lists.bham.ac.uk providing details and we will remove access to the work immediately and investigate.

1 **Modulation of neutrophil extracellular trap (NET) and reactive**
2 **oxygen species (ROS) release by periodontal bacteria**

3
4 **Running title: NET and ROS release in response to oral bacteria**

5
6 **Authors:**

7 Josefine Hirschfeld^{1,*,#}, Phillipa C. White^{1*,§}, Michael R. Milward¹, Paul R. Cooper¹,
8 Iain L.C. Chapple^{1,#}

9
10 ¹ Periodontal Research Group, Birmingham Dental School and Hospital, Institute of
11 Clinical Sciences, The University of Birmingham and Birmingham Community Health
12 NHS Trust, 5 Mill Pool Way, Edgbaston, Birmingham B5 7EG, United Kingdom

13
14
15 **# Correspondence:**

16 Dr Josefine Hirschfeld
17 Birmingham Dental School and Hospital, Periodontal Research Group
18 5 Mill Pool Way, Birmingham B5 7EG, United Kingdom

19 **Phone:** +44 121 466 5114; **E-mail:** j.hirschfeld@bham.ac.uk

20
21 Prof Iain L. C. Chapple
22 Birmingham Dental School and Hospital, Periodontal Research Group
23 5 Mill Pool Way, Birmingham B5 7EG, United Kingdom

24 **Phone:** +44 121 466 5496; **E-mail:** i.l.c.chapple@bham.ac.uk

25

26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50

Footnotes:

* Both authors contributed equally

§ Author's current address: DRG Abacus International, Talisman Rd, Bicester OX26
6HR, UK

Corresponding authors' e-mail addresses: j.hirschfeld@bham.ac.uk;
i.l.c.chapple@bham.ac.uk

Keywords:

Neutrophils, NETs, reactive oxygen species, periodontitis, oral bacteria

51 **ABSTRACT**

52

53 **Background:** Oral bacteria are the main trigger for the development of periodontitis
54 and some species are known to modulate neutrophil function. This study aimed to
55 explore the release of neutrophil extracellular traps (NETs), associated antimicrobial
56 proteins and reactive oxygen species (ROS) in response to periodontal bacteria, as
57 well as the underlying pathways.

58 **Methods:** Isolated peripheral blood neutrophils were stimulated with 19 periodontal
59 bacteria. NET and ROS release as well as the expression of NET-bound
60 antimicrobial proteins, elastase, myeloperoxidase and cathepsin G, in response to
61 these species were measured using fluorescence-based assays. NET and ROS
62 release were monitored after the addition of nicotinamide adenine dinucleotide
63 phosphate (NADPH)-oxidase pathway modulators and inhibitors of Toll-like
64 receptors (TLRs). Moreover, bacterial entrapment by NETs was visualised
65 microscopically and bacterial killing was assessed by bacterial culture.

66 **Results:** Certain microorganisms, e.g. *Veillonella parvula* and *Streptococcus*
67 *gordonii*, stimulated higher ROS and NET release than others. NETs were found to
68 entrap, but not kill, all periodontal bacteria tested. NADPH-oxidase pathway
69 modulators decreased ROS but not NET production in response to the bacteria.
70 Interestingly, TLR inhibitors did not impact on ROS and NET release.

71 **Conclusions:** These data suggest that the variability in neutrophil response towards
72 different bacteria may contribute to the pathogenesis of periodontal diseases by
73 mechanisms such as bacterial avoidance of host responses and activation of
74 neutrophils. Moreover, our results indicate that bacteria-stimulated NET release may

75 in part arise via NADPH oxidase-independent mechanisms. The role of TLR
76 signalling in bacteria-induced ROS and NET release needs to be further elucidated.

77

78

79

80

81

82

83

84

85

86

87

88

89

90

91

92

93

94

95

96

97

98

99

100 **INTRODUCTION**

101

102 Periodontitis is initiated by the accumulation of microbial biofilms at and below the
103 gingival margin. Indeed it has been estimated that ~700 oral bacterial species and
104 ~1,200 predominant phylotypes exist (1-3). Of these bacterial species, 5 major
105 bacterial complexes (red, orange, yellow, green and purple) have been identified by
106 Socransky *et al.* using DNA probes (4). The clustering and ordination analysis
107 allowed them to assign microbial species to a colour complex dependent upon the
108 strength of association with each other and the clinical staging of periodontitis. The
109 biofilms, which develop during disease, are orchestrated to maximise their
110 adherence, communication and survival. The accumulation of bacterial species
111 within the biofilm enables its development and perseverance, and certain bacteria,
112 such as *Fusobacterium nucleatum* (*F. nucleatum*), are key orchestrators of biofilm
113 formation and maturation (5).

114

115 In susceptible individuals, dysbiosis and an aberrant host-microbial equilibrium can
116 result in the onset of disease (6), where the microbial biofilm thrives by exploiting the
117 host inflammatory response. This process fuels a vicious cycle of bacterial
118 accumulation, inflammation and subsequent tissue destruction. The acute
119 inflammatory reaction is predominantly mediated by neutrophils and is initially
120 protective, via activation of innate neutrophil-derived defence mechanisms and also
121 the activation of the acquired cellular and humoral immune system. In periodontitis,
122 however, the aberrant neutrophil response is reputed to contribute to collateral tissue
123 damage and formation of disease-associated molecular patterns, which perpetuate
124 the inflammation leading to chronicity (7). Furthermore, the inflammatory state itself

125 supplies nutrients to pathogenic bacteria such as *Porphyromonas gingivalis* (*P.*
126 *gingivalis*), e.g. iron from heme, supporting its survival and proliferation (8).

127

128 An exaggerated immune activity is also observed in peripheral blood neutrophils
129 from both chronic and aggressive periodontitis patients. These neutrophils are
130 reportedly hyper-reactive in response to a microbial challenge in terms of their
131 release of reactive oxygen species (ROS), but also hyperactive in the absence of an
132 exogenous stimulus (9-11). In addition, excessive neutrophil-driven proteolytic
133 activity and pro-inflammatory cytokine production have been observed in
134 periodontitis and associate with pathogenicity (7). One of the mechanisms by which
135 neutrophils combat microorganisms through the production of neutrophil extracellular
136 traps (NETs), whereby decondensed DNA is released into the extracellular
137 environment to immobilise and potentially kill invading bacteria. NET release is
138 reported to be dependent on the production of ROS, such as hydrogen peroxide
139 (H_2O_2), via superoxide generation by the enzyme NADPH oxidase (12).

140

141 Little is known about the differential interactions between oral bacteria and
142 neutrophils, however there is evidence that certain species and strains can evoke
143 different neutrophil responses (13-16). This study aimed to elucidate the ability of
144 bacterial species and strains frequently isolated from the oral cavity of healthy and
145 diseased individuals to activate ROS and NET responses in neutrophils. The ability
146 of NETs to entrap and kill bacteria, along with the expression of the antimicrobial and
147 NET-associated proteins neutrophil elastase (NE), myeloperoxidase (MPO) and
148 cathepsin G (CG) were also analysed.

149

150

151 **RESULTS**

152

153 **Neutrophil ROS release in response to periodontal bacteria**

154 The production of total ROS, extracellular ROS and superoxide in response to 19
155 periodontal bacteria and *S. aureus* (**Table 1**) were determined. Certain bacteria
156 elicited higher total ROS production in neutrophils, which was measured by luminol
157 chemiluminescence. This was statistically significant for *P. acnes*, *S. anginosus* and
158 *C. rectus* as well as the positive control opsonised *S. aureus* (**Figure 1A**). Consistent
159 with the data expressed as total peak ROS production, time-course ROS production
160 expressed as “area under the curve” demonstrated that ROS production was highest
161 in response to opsonised *S. aureus* followed by *S. anginosus*. Notably, the increase
162 in total ROS in response to opsonised *S. aureus* was more rapid than following direct
163 stimulation with periodontal bacteria, as illustrated by the sharp elevation of the
164 curve immediately following stimulation. Neutrophil extracellular ROS production was
165 subsequently analysed by isoluminol chemiluminescence. Phorbol 12-myristate 13-
166 acetate (PMA; positive control) and *S. gordonii* induced significantly higher
167 extracellular ROS than PBS treatment (negative control) (**Figure 1B**). The steep
168 time-course curve in response to PMA indicates a rapid neutrophil response.
169 Neutrophil extracellular superoxide production was measured using lucigenin. PMA
170 and opsonised *S. aureus* did not induce significantly higher superoxide production
171 relative to the PBS control. However, some periodontal bacteria increased
172 extracellular superoxide production in neutrophils, which was statistically significant
173 for *S. anginosus*, *C. sputigena*, and *F. nucleatum subsp. nucleatum* (**Figure 1C**).

174

175 **Quantification of NET production in response to periodontal bacteria**

176 NET release in response to the bacterial challenge was quantified. Some bacteria
177 led to an enhanced NET-DNA production, which was statistically significant for *P.*
178 *acnes*, *V. parvula*, and *S. gordonii* compared with the PBS control (**Figure 2A**). NET-
179 bound NE, MPO and CG were quantified colorimetrically and data demonstrated that
180 certain periodontal bacteria elicited an increased production of NET-bound proteins
181 relative to PBS (**Figure 2B-D**). Similarly, stimulation with PMA and opsonised
182 *S. aureus* (positive controls) induced statistically significant elevations in MPO and
183 CG expression (**Figures 2C and D**).

184

185 **NET entrapment of bacteria does not associate with Socransky complexes or**
186 **with bacterial cell death**

187 For clinical relevance, data are presented by grouping periodontal bacteria according
188 to the Socransky complexes (4) (**Figure 3A**). Non-Socransky complex: *I. noxia* and
189 *V. parvula* were found to be entrapped within NET structures in higher numbers
190 compared to the negative controls (unstimulated neutrophils or degraded NETs)
191 However, neither *A. actinomycetemcomitans* (serotype b) nor *P. acnes* or *A.*
192 *viscosus* were significantly associated with NET entrapment. Yellow complex: *S.*
193 *anginosus* and *S. gordonii* were significantly entrapped within NETs. However, the
194 other yellow complex bacteria assayed, *S. sanguinis*, *S. oralis* and *S. intermedius*,
195 were not found within NET structures. Green complex: none of the green complex
196 bacteria assayed appeared within NETs at a significant level. Orange complex: *C.*
197 *rectus*, *C. showae* and *F. nucleatum* subsp. *polymorphum* were significantly
198 entrapped within NETs relative to the negative controls, whereas *S. constellatus* and
199 *F. nucleatum* subsp. *nucleatum* were not. Red complex: *P. gingivalis* was

200 significantly associated with NET structures compared with bacteria incubated with
201 unstimulated neutrophils or degraded NET structures. SEM images of unstimulated
202 neutrophils demonstrated spherical cells with no NET structures evident, whereas
203 neutrophils incubated with *A. actinomycetemcomitans* serotype a, *V. parvula* and *A.*
204 *viscosus* revealed the release of NET structures (**Figure 3B**). The strand-like
205 filaments between the neutrophils appeared to associate with bacteria, for example,
206 *A. actinomycetemcomitans* (serotype a) clustered along NET structures. The
207 bacterial killing assays employed to detect the microbicidal properties of NETs
208 revealed that the viability of the 6 periodontal bacteria tested was unaffected by NET
209 trapping (**Figure 3C**).

210

211 **Effect of NADPH-oxidase pathway modulating agents on ROS and NET** 212 **production**

213 Components of the NADPH-oxidase signalling pathway were targeted in order to
214 assess whether NADPH-oxidase is essential for neutrophil ROS and NET production
215 in response to periodontal bacteria. The data show that diphenyleneiodonium (DPI;
216 NADPH-oxidase inhibitor), N-acetyl-cysteine (NAC; H₂O₂ scavenger) and taurine
217 (HOCl scavenger) treatment resulted in a reduction in total ROS release in response
218 to all stimuli. This was statistically significant for PMA, opsonised *S. aureus*, *S.*
219 *gordonii*, *C. rectus*, *F. nucleatum* subsp. *polymorphum* and *S. noxia* (**Figure 4A**).
220 NET production was, with the exception of PMA, not significantly affected by these
221 inhibitors, however, a moderate reduction of NET release was visible in all samples
222 (**Figure 4B**).

223

224 **Effect of Toll-like receptor (TLR) inhibition on ROS and NET production**

225 The role of TLR signalling in neutrophil ROS and NET responses to periodontal
226 bacteria was investigated by using specific inhibitors. Chloroquine (TLR3, 7 and 9
227 inhibitor) and oxidised 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine
228 (OxPAPC; (TLR2 and 4 inhibitor) treatment as well as treatment with both
229 components did not reduce ROS production by neutrophils. However, a significant
230 increase in ROS release from neutrophils treated with OxPAPC and opsonised *S.*
231 *aureus* was seen (**Figure 5A**). Similarly, NET release in response to bacterial
232 stimulation was not affected by the TLR inhibitors (**Figure 5B**).

233

234

235 **DISCUSSION**

236

237 Neutrophil ROS production is a vital component of the innate immune response,
238 which enables killing and clearance of pathogens. Neutrophils are the predominant
239 immune cell in periodontitis (17), and the results presented here support that their
240 stimulation with periodontal bacteria promotes extracellular, intracellular and
241 superoxide ROS release; however data indicate that this may be species specific.
242 Indeed, some species consistently elicited higher neutrophil ROS production while
243 other bacteria, such as *P. gingivalis* or *S. sanguinis*, were not found to significantly
244 promote ROS release. Bacteria like *P. gingivalis*, *F. nucleatum* and oral streptococci
245 can scavenge neutrophil-derived ROS production, which is attributed to a range of
246 oxidative stress response genes encoding proteins like rubrerythrin, glutathione
247 peroxidase, glutaredoxin, NADH oxidase and superoxide dismutase (18-22). It is
248 possible that these bacterial defence mechanisms may function to afford protection
249 to other biofilm organisms that are less resistant to ROS.

250

251 Periodontitis is known to arise from an exaggerated inflammatory response to
252 microbial plaque (6). Whilst it is recognised that ROS facilitate microbial killing, ROS
253 do not discriminate between pathogens and host tissues, and therefore tissue injury
254 can arise from excess plaque-induced extracellular ROS release. ROS are reported
255 to contribute to periodontitis progression by direct and indirect mechanisms,
256 including tissue damage (23, 24), lipid peroxidation (25), DNA strand breakage (26),
257 increased osteoclast differentiation (27) and initiation of a self-perpetuating cycle that
258 activates chronic immune cell-derived ROS production (28). Notably, Matthews *et al.*
259 showed an increased ROS production by peripheral blood neutrophils in chronic
260 periodontitis (9, 10). In patients susceptible to the deleterious effects of ROS, a
261 discordance between oxidant and antioxidant levels may also play a role. This is
262 supported by Chapple *et al.*, who demonstrated that total antioxidant activity is lower
263 in the saliva of periodontitis patients (29). It has also been reported that neutrophil
264 chemotaxis is compromised in chronic periodontitis, and that these patients'
265 neutrophils produce the chemoattractant interleukin-8 in excess when stimulated,
266 potentially creating distracted chemotaxis (30). Such processes may increase
267 neutrophil tissue transit times and thereby potentially exacerbating ROS-mediated
268 collateral tissue damage (17).

269

270 Quantification of NET-DNA and NET-bound antimicrobial proteins demonstrated
271 differential NET production in response to the periodontal bacteria tested. DNA is
272 released during other forms of neutrophil cell death, such as necrosis, and the
273 quantification of NET-bound components (NE, MPO and CG) therefore provides a
274 DNA-independent measure of NETs. It is noteworthy that differences between

275 individuals have been reported, such as neutrophil responsiveness to stimuli, which
276 can also affect NET quantification results regardless of the analytical method
277 employed (31, 32). Significant NET production in response to individual periodontal
278 bacteria, however, indicates these events likely occur *in vivo*. Notably, NETs have
279 previously been shown to exist in purulent exudate from periodontal pockets, where
280 they are postulated to entrap invading microbes and prevent their dissemination (33,
281 34). Recently, many periodontal bacterial species have been shown to release
282 DNAses, which in addition to regulating biofilm formation (35), can potentially
283 disassemble NET structures to enable NET evasion (36). Thus, bacterial DNase
284 expression may explain why some periodontal species showed less entrapment,
285 such as *S. constellatus*, which reportedly releases large quantities of DNase (36).

286

287 Following bacterial entrapment, the high local concentration of antimicrobial proteins
288 associated with NETs is thought to disable and kill pathogens (37). In the present
289 study, the incubation of NETs with periodontal bacteria did not impede bacterial
290 growth or survival, being in accordance with data reported by Menegazzi *et al.* (38).
291 Cytochalasin B was applied in our study to exclude the possibility of bacterial killing
292 through phagocytosis and this inhibition occurs via blocking of actin polymerization
293 (39). As functional actin filaments may play a role in NET formation (40), it is
294 possible that cytochalasin B interfered with NET and antimicrobial protein release in
295 our study and thus prevented bacterial killing. However, other known inhibitors of
296 phagocytosis and endocytosis such as Latrunculin A or CK666 also exert their
297 effects by disturbing actin polymerisation (41, 42). Future experiments may be
298 directed at investigating differences among such inhibitors regarding their
299 interference with NET release.

300

301 Treatment of neutrophils with the NADPH-oxidase inhibitor DPI, glutathione
302 peroxidase precursor substrate NAC and the HOCl scavenger taurine abrogated
303 total ROS release, being in accordance with data previously reported (43-45). NET
304 release was only inhibited marginally in response to the bacterial challenge. At the
305 same time, NET production was significantly affected by the inhibitors in neutrophils
306 stimulated with PMA. This may be explained by the fact that PMA induces NETs via
307 protein kinase C, which then activates the NADPH oxidase, and thus can elicit NETs
308 only via the generation of ROS (43). These findings indicate that NADPH-oxidase-
309 independent NET formation may play a role in host defence against periodontal
310 bacteria (46, 47).

311

312 Further experiments aimed to establish the role of TLR activation in NET production.
313 Pre-treatment of neutrophils with the intracellular TLR3, 7, 8 and 9 inhibitor
314 chloroquine and with the TLR2 and 4 inhibitor OxPAPC separately or combined, did
315 not lead to significant reductions in ROS or NET release. Previous findings have
316 suggested that ROS release is both TLR2 and 4 dependent (48), however, Gould *et*
317 *al.* recently demonstrated that blocking TLR2 and 4 did not abolish NET release (49),
318 being in line with the findings of this study. Notably, neutrophils are not responsive to
319 TLR3 ligands (50), therefore, the involvement of TLR7, 8 and 9 was investigated by
320 using chloroquine. Similarly, to our results, Salmon *et al.* found that chloroquine had
321 no effect on the oxidative metabolism in neutrophils (51). Thus, a lack of inhibition
322 of ROS and NET generation by chloroquine and OxPAPC indicates that other
323 signalling pathways may have played a role in this study. For example, C-type lectin
324 receptors and NOD-like receptors can be activated by bacterial triggers, and both

325 have been reported to induce immune activation in neutrophils, including the release
326 of ROS (52, 53). Moreover, signalling via TLR co-receptors may have bypassed the
327 inhibited pathways (54). Importantly, although widely used as a TLR inhibitor,
328 chloroquine is thought to directly interfere with multiple physiological cell functions
329 including chemotaxis, phagocytosis and ROS release, by alkalinising lysosomes and
330 phagolysosomes (55, 56). Our results do not support an inhibitory effect of
331 chloroquine on these functions in the concentrations applied in the present study, as
332 no significant differences were seen between neutrophils treated with chloroquine
333 and negative controls. However, results from functional cell assays using
334 chloroquine as an inhibitor should be interpreted with care.

335

336 Future experiments should target these receptors to further elucidate their specific
337 role in ROS and NET release. Interestingly, in OxPAPC-treated neutrophils
338 stimulated with opsonised *S. aureus*, a significant increase in ROS was seen.

339 Previous studies reported that OxPAPC has the potential to increase ROS release in
340 endothelial cells via activating the NADPH oxidase (57, 58). Moreover, Fc gamma
341 receptor (FcγR) signalling is known to trigger ROS release (59). It is therefore
342 possible that OxPAPC may act as a co-trigger of FcγR-mediated ROS release in
343 neutrophils challenged with opsonised bacteria, however, further experiments are
344 required to confirm this hypothesis.

345

346 As a limitation of this study, planktonic single-species preparations were used to
347 stimulate neutrophils. *In vivo*, however, neutrophils are challenged by multi-species
348 biofilms. These biofilms produce metabolites and extracellular matrix components
349 that may lead to a different response pattern compared to that observed under our

350 experimental conditions. Variability in these extracellular products generated by
351 naturally or artificially grown biofilms is high and reproducibility of experiments
352 involving such biofilms is difficult (13, 60). Moreover, natural dental biofilms are
353 highly variable in their composition, and it is difficult to attribute their activation of
354 neutrophils to certain species or biofilm components. Therefore, little is know about
355 the interactions between host cells and mixed species biofilms. Further efforts aimed
356 at creating a reproducible neutrophil-biofilm interaction model *in vitro* are currently
357 being carried out by our group. Nevertheless, in order to understand the interaction
358 of neutrophils with oral bacterial species, such microorganisms playing key roles in
359 neutrophil activation need to be identified and investigated separately. Insights from
360 these experiments may subsequently allow for better understanding of neutrophil
361 responses to oral biofilms.

362

363 As a further limitation, heat-killed microorganisms were employed in our study.
364 Although heat-killing may lead to the denaturation of surface antigens and pathogen-
365 associated molecular patterns (PAMPs), this is thought to be reversible at
366 temperatures below 80°C (61). Moreover, previous studies using live bacteria (*A.*
367 *actinomycetemcomitans* serotype b or *S. gordonii*, *F. nucleatum* subsp.
368 *polymorphum* and *V. parvula*) showed similar NET formation outcomes regarding
369 AFU measurements or relative differences in NET production, respectively (14, 62).
370 Another restriction in our study is the limited number of different bacterial species
371 used to investigate neutrophil activation. Future studies may need to include further
372 species, particularly of the red complex, such as *Treponema denticola* and
373 *Tannerella forsythia*.

374

375 In the present study, neutrophils from periodontally and systemically healthy donors
376 were used. Overall, these neutrophils were responsive to some health-associated
377 species and opportunistic pathogens rather than disease-associated species. By
378 contrast, our previous investigations of periodontally diseased patients have shown
379 that their neutrophils are hyperactive and hyper-reactive towards *F. nucleatum* and
380 *P. gingivalis* in terms of ROS and cytokine release. On the other hand, NET
381 production in response to various stimuli was not altered and was similar in
382 periodontitis patients and non-periodontitis controls. However, these studies did not
383 compare the effect of health- and disease-associated bacteria on neutrophils (9, 30,
384 63, 64). It is possible that neutrophils from periodontitis patients may show a higher
385 reactivity towards periodontal bacteria than those from healthy subjects, as these
386 neutrophils may be primed in the circulation by bacterial components, such as LPS,
387 accessing the blood stream through periodontal microlesions (65, 66). Further
388 studies examining responses of neutrophils from healthy and periodontally diseased
389 individuals to different oral bacteria may shed light on possible mechanisms of
390 immune tolerance in health and disease.

391

392 In summary, the data presented here demonstrate variability between periodontal
393 bacteria in their ability to stimulate neutrophil ROS production and NET responses.
394 This may contribute to the pathogenesis of periodontitis by mechanisms such as
395 bacterial avoidance of host defence mechanisms and thus persistence of infection,
396 or excess ROS release with associated tissue damage. Moreover, our results
397 indicate that innate immune receptors other than the TLRs investigated here may be
398 involved in bacteria-triggered ROS and NET release, and that NADPH oxidase-
399 independent NET formation may occur in response to periodontal pathogens.

400 Comprehensive studies are required to fully elucidate the role of NETs and ROS in
401 periodontitis, in particular with regard to the receptors, activation pathways and
402 intracellular responses triggered by different bacteria. Also, investigating the possible
403 activation of protective mechanisms, such as glutathione up-regulation, or of anti-
404 inflammatory signalling routes by these bacteria may improve our understanding of
405 their differential effects seen in this study.

406

407

408 **MATERIALS AND METHODS**

409

410 **Neutrophil isolation**

411 Neutrophils were isolated from the peripheral venous blood of periodontally and
412 systemically healthy volunteers (University of Birmingham Ethics Reference:
413 ERN_13-0325) using discontinuous Percoll gradients (GE Healthcare, Amersham,
414 UK) as previously described (67). The medical history was taken from each donor
415 and periodontal examinations were conducted to ensure periodontal and systemic
416 health. Cell viability and purity were confirmed by trypan blue exclusion and flow
417 cytometry, respectively, and this was typically >98%.

418

419 **Bacterial culture**

420 A panel of 19 periodontal bacteria and opsonised *S. aureus* were employed to
421 stimulate neutrophils. Bacterial stocks were originally obtained from the Forsyth
422 Institute (Boston, MA, USA) or purchased from the American Type Culture Collection
423 (ATCC). Blood agar plates (Base no. 2 with 7% horse blood) were purchased from
424 Oxoid (Basingstoke, UK) and used for growing most bacterial strains. *P. gingivalis*

425 (strain W83) was cultured on anaerobic 20% blood agar plates (Wilkins Chalgren,
426 Oxoid) and *S. aureus* was cultured on tryptone soya agar (TSA) plates. Trypticase
427 soy broth (TSB), brain heart infusion broth (BHI) (both from Oxoid) or fastidious
428 anaerobe broth (Lab M, Heywood, UK) were used for planktonic growth of the
429 microorganisms. Bacterial cell suspensions were measured spectrophotometrically
430 at an optical density of 600 nm to estimate bacterial numbers and bacteria were
431 heat-killed at 80°C for 30 min. Bacterial cells were washed with PBS, centrifuged and
432 the pellet resuspended to produce a stock solution, which was stored at -20°C prior
433 to use. The bacteria used, their growth conditions and assignment to Socransky
434 complexes are listed in **Table 1**.

435

436 **Opsonisation of *S. aureus***

437 *S. aureus* was grown planktonically in TSB. Following 48h of aerobic growth,
438 bacteria were washed and pelleted by centrifugation for 15 min at 1800 rcf and 4°C.
439 Bacteria were opsonised with Vigam liquid (5 mg/mL IgG, Bio Products Laboratory,
440 Borehamwood, UK). This mixture was agitated overnight at room temperature and,
441 after washing, stored at -20°C until needed.

442

443 **Stimuli employed to activate neutrophils**

444 Neutrophils were stimulated using a range of stimuli. PMA targets NET production
445 via the activation of protein kinase C (PKC). Our previous findings demonstrated that
446 the concentration of PMA required for NET release is at 50 nM, whereas 25 nM are
447 sufficient to stimulate ROS production (43). Both Gram-positive and -negative
448 bacteria were used to activate neutrophils via TLR2 and 4 in ROS and NET assays.
449 In addition, ROS and NETs were produced in response to stimulation with opsonised

450 *S. aureus*, which activates neutrophils via the FcγR. For some supplementary
451 assays, a smaller panel of bacteria was employed, where the selection was made
452 based on variable characteristics of the microorganisms: *Gram*-positive and *Gram*-
453 negative, aerobic, anaerobic and microaerophilic bacteria from different complexes
454 with FcγR and TLR activation properties were chosen, and both health and disease-
455 associated bacteria were represented. Moreover, variable DNase production was a
456 selection criterion, as DNases have the ability to disassemble NETs (e.g., *F.*
457 *nucleatum* and *S. aureus* are known to produce DNase, whereas *A. viscosus* and *V.*
458 *parvula* produce little or no DNase, respectively) (36). In addition, bacteria reported
459 to interfere with ROS scavenging were included: *F. nucleatum* and *S. noxia*, which
460 can metabolise the antioxidants glutathione and L-cysteine (68), as well as *A.*
461 *viscosus*, which produces the ROS scavenger catalase (69).

462

463 **Quantification of NET production in response to periodontal bacteria**

464 NET release was determined using a NET quantification assay previously described
465 (70). Neutrophils were stimulated with the positive controls PMA (50 nM) and
466 opsonised *S. aureus* as well as with 19 heat-killed periodontal bacteria (multiplicity of
467 infection [MOI] of 1,000 (71)) after being equilibrated for a 30 min baseline period.
468 Unstimulated neutrophils (PBS) were employed as negative controls. Neutrophils
469 from 10 periodontally and systemically healthy donors were used to perform NET
470 quantification in triplicate wells per donor.

471

472 **Chemiluminescence protocol for ROS assay**

473 ROS production in response to the periodontal bacteria (MOI of 1,000) was
474 determined using enhanced chemiluminescence. Neutrophils (1×10^5) from five

475 different donors were added to a 96-well plate (using triplicate wells per donor) pre-
476 coated with 1% bovine serum albumin (BSA). ROS release following exposure to
477 PBS (unstimulated negative control), PMA (25 nM, positive control) and opsonised
478 *S. aureus* (MOI of 500, positive control) was quantified. Neutrophils were stimulated
479 after being equilibrated for a 30 min baseline period and then ROS was measured
480 over the subsequent 100 min. To measure total ROS, extracellular ROS and
481 superoxide, luminol (3 mM), isoluminol (3 mM) with 1.5 units of horseradish
482 peroxidase (HRP), and lucigenin (0.25 mg/mL), respectively, were added to the
483 samples and the light output was read for 130 min in a luminometer (Berthold
484 Tristar2, Berthold Technologies, Harpenden, UK). All readings were expressed as
485 relative light units (RLUs) and read at 37°C (MikroWin2000, Informer Technologies,
486 Madrid, Spain). All reagents for chemiluminescence were purchased from Sigma
487 Aldrich (Dorset, UK).

488

489 **NET entrapment and quantification of NET-mediated killing of periodontal** 490 **bacteria**

491 To assess the ability of NETs to immobilise periodontal bacteria, fluorescein
492 isothiocyanate (FITC)-stained live bacteria (MOI of 100) were incubated for 1h with
493 unstimulated neutrophils, intact NETs (produced by prior 0.75 mM HOCl stimulation
494 with a subsequent washing step (43)) or NET structures degraded with micrococcal
495 nuclease (MNase, New England Biolabs, Hitchin, UK) in a 96-well plate pre-coated
496 with 1% BSA, using five different donors and triplicate wells per donor. *In vitro* NETs
497 are formed within 2-3h, therefore, a relevant induction of NET release from otherwise
498 unstimulated neutrophils by bacteria could be excluded. Following multiple wash
499 steps to remove any unbound bacteria, the amount of bacteria entrapped was

500 fluorometrically quantified and normalised to FITC-stained bacteria incubated with
501 PBS (cell-free control). To determine whether NETs are capable of killing entrapped
502 bacteria, six strains (*F. nucleatum* subsp. *polymorphum*, *S. intermedius*, *S.*
503 *sanguinis*, *A. viscosus*, *V. parvula* and *C. gingivalis*) were incubated at a MOI of 100
504 with PBS (negative control), unstimulated neutrophils, intact NETs or degraded
505 NETs from five different donors in triplicate wells per donor. Additionally, samples
506 containing neutrophils were treated with the phagocytosis inhibitor cytochalasin B
507 (Sigma Aldrich, Harpenden, UK) at a concentration of 10 µg/mL (72). Following 1h of
508 incubation bacteria were released from NETs by MNase digestion, diluted and
509 inoculated onto agar plates and cultured for 24h prior to performing colony counts.

510

511 **Effect of NADPH-oxidase pathway modulating agents on ROS and NET**

512 **production**

513 To further understand the importance of NADPH-oxidase and downstream products
514 in bacteria-induced ROS and NET production, specific components of the NADPH-
515 oxidase signalling pathway were targeted. Isolated neutrophils from three different
516 donors were incubated with DPI (25 µM), an inhibitor of NADPH-oxidase, NAC
517 (10 mM), a synthetic glutathione precursor that scavenges H₂O₂, or taurine
518 (100 mM), which scavenges HOCl to produce taurine chloramine (duplicate wells per
519 donor). Neutrophil total ROS and NET production were measured following pre-
520 incubation with the modulating agent for 30 min prior to stimulation with PMA
521 (50 nM), opsonised *S. aureus* (MOI of 500) and 8 selected bacteria (MOI of 1000; *S.*
522 *aureus*, *V. parvula*, *F. nucleatum* subsp. *nulceatum*, *F. nucleatum* subsp.
523 *polymorphum*, *S. gordonii*, *C. rectus*, *A. viscosus* and *S. noxia*). NET-DNA was
524 quantified with Sytox Green following enzymatic degradation of NET structures with

525 MNase. All reagents were purchased from Sigma Aldrich (Dorset, UK).

526

527 **Effect of TLR inhibition on ROS and NET production**

528 To better understand the signalling involved in ROS and NET activation, the effect of
529 TLR inhibitors was investigated. Isolated neutrophils from three different donors were
530 incubated in duplicate wells per donor with chloroquine (100 µM, Invivogen,
531 Toulouse, France), an intracellular inhibitor of endosomal TLR 3, 7, 8 and 9, or
532 OxPAPC (30µg/ml, Invivogen, Toulouse, France), which inhibits intracellular
533 signalling of activated TLR 2 and 4, or both TLR inhibitors were used simultaneously.
534 Neutrophil total ROS and NET production were measured following pre-incubation
535 with the inhibitor for 30 min prior to stimulation with PMA (50 nM), opsonised *S.*
536 *aureus* (MOI of 500) and 8 selected bacteria (MOI of 1000; *S. aureus*, *V. parvula*, *F.*
537 *nucleatum* subsp. *nulceatum*, *F. nucleatum* subsp. *polymorphum*, *S. gordonii*, *C.*
538 *rectus*, *A. viscosus* and *S. noxia*).

539

540 **Statistical analysis**

541 All statistical analyses were performed in GraphPad Prism 5 software package for
542 Windows (San Diego, CA, USA). The distribution of data, and thus whether data
543 were considered parametric or non-parametric, was determined by Kolmogorov-
544 Smirnov tests. Statistical tests employed for the purpose of this study were at a
545 significance of 0.05. The level of significance is indicated as follows: *, **, *** and ****
546 denotes <0.05, <0.01, <0.001 and <0.0001, respectively. Kruskal-Wallis and Dunn's
547 multiple comparison tests were performed for quantification of ROS and NET
548 release. One-way ANOVA and Dunnett's post-hoc tests were employed for NET
549 entrapment assays. Two-way ANOVA and Bonferroni post-hoc tests were applied to

550 calculate significances of pathway modulation and inhibition assays. All quantitative
551 data are shown as mean values \pm standard deviations and all statistical tests were
552 performed comparing different donors.

553

554

555 **ACKNOWLEDGMENTS**

556

557 The authors would like to thank Dr Helen Wright and Dr Naomi Hubber for their
558 technical support. We are also grateful to Dr Iru Dias, who helped with the flow
559 cytometry. This research was funded by the University of Birmingham Dental School,
560 the Medical Research Council (MR/J500434/1), the British Society of Periodontology
561 and the Oral & Dental Research Trust (14945). This manuscript has arisen from Dr
562 Phillipa White's Ph.D. thesis (see references). The authors declare that there is no
563 conflict of interest regarding the publication of this paper.

564

565

566 **REFERENCES**

567

- 568 1. Paster BJ, Dewhirst FE. 2009. Molecular microbial diagnosis. *Periodontol*
569 2000 51:38-44.
- 570 2. Kilian M, Chapple IL, Hannig M, Marsh PD, Meuric V, Pedersen AM, Tonetti
571 MS, Wade WG, Zaura E. 2016. The oral microbiome - an update for oral
572 healthcare professionals. *Br Dent J* 221:657-666.
- 573 3. Dewhirst FE, Chen T, Izard J, Paster BJ, Tanner AC, Yu WH, Lakshmanan A,
574 Wade WG. 2010. The human oral microbiome. *J Bacteriol* 192:5002-5017.

- 575 4. Socransky SS, Haffajee AD, Cugini MA, Smith C, Kent RL, Jr. 1998. Microbial
576 complexes in subgingival plaque. *J Clin Periodontol* 25:134-144.
- 577 5. Kolenbrander PE, Palmer RJ, Jr., Periasamy S, Jakubovics NS. 2010. Oral
578 multispecies biofilm development and the key role of cell-cell distance. *Nat*
579 *Rev Microbiol* 8:471-480.
- 580 6. Hajishengallis G. 2014. Immunomicrobial pathogenesis of periodontitis:
581 keystones, pathobionts, and host response. *Trends Immunol* 35:3-11.
- 582 7. Scott DA, Krauss J. 2012. Neutrophils in periodontal inflammation. *Front Oral*
583 *Biol* 15:56-83.
- 584 8. Hajishengallis G, Lamont RJ. 2014. Breaking bad: manipulation of the host
585 response by *Porphyromonas gingivalis*. *Eur J Immunol* 44:328-338.
- 586 9. Matthews JB, Wright HJ, Roberts A, Cooper PR, Chapple IL. 2007.
587 Hyperactivity and reactivity of peripheral blood neutrophils in chronic
588 periodontitis. *Clin Exp Immunol* 147:255-264.
- 589 10. Matthews JB, Wright HJ, Roberts A, Ling-Mountford N, Cooper PR, Chapple
590 IL. 2007. Neutrophil hyper-responsiveness in periodontitis. *J Dent Res*
591 86:718-722.
- 592 11. Shapira L, Borinski R, Sela MN, Soskolne A. 1991. Superoxide formation and
593 chemiluminescence of peripheral polymorphonuclear leukocytes in rapidly
594 progressive periodontitis patients. *J Clin Periodontol* 18:44-48.
- 595 12. Fuchs TA, Abed U, Goosmann C, Hurwitz R, Schulze I, Wahn V, Weinrauch
596 Y, Brinkmann V, Zychlinsky A. 2007. Novel cell death program leads to
597 neutrophil extracellular traps. *J Cell Biol* 176:231-241.
- 598 13. Hirschfeld J. 2014. Dynamic interactions of neutrophils and biofilms. *J Oral*
599 *Microbiol* 6:26102.

- 600 14. Hirschfeld J, Dommisch H, Skora P, Horvath G, Latz E, Hoerauf A, Waller T,
601 Kawai T, Jepsen S, Deschner J, Bekeredjian-Ding I. 2015. Neutrophil
602 extracellular trap formation in supragingival biofilms. *Int J Med Microbiol*
603 305:453-463.
- 604 15. Palmer LJ, Damgaard C, Holmstrup P, Nielsen CH. 2016. Influence of
605 complement on neutrophil extracellular trap release induced by bacteria. *J*
606 *Periodontal Res* 51:70-76.
- 607 16. Guentsch A, Puklo M, Preshaw PM, Glockmann E, Pfister W, Potempa J, Eick
608 S. 2009. Neutrophils in chronic and aggressive periodontitis in interaction with
609 *Porphyromonas gingivalis* and *Aggregatibacter actinomycetemcomitans*. *J*
610 *Periodontal Res* 44:368-377.
- 611 17. Roberts HM, Ling MR, Insall R, Kalna G, Spengler J, Grant MM, Chapple IL.
612 2015. Impaired neutrophil directional chemotactic accuracy in chronic
613 periodontitis patients. *J Clin Periodontol* 42:1-11.
- 614 18. Mydel P, Takahashi Y, Yumoto H, Sztukowska M, Kubica M, Gibson FC, 3rd,
615 Kurtz DM, Jr., Travis J, Collins LV, Nguyen KA, Genco CA, Potempa J. 2006.
616 Roles of the host oxidative immune response and bacterial antioxidant
617 rubrerythrin during *Porphyromonas gingivalis* infection. *PLoS Pathog* 2:e76.
- 618 19. Park S-N, Cho E, Kim H-S, Kim D-S, Jung J, Baek J-H, Kyong Lim Y, Jo E,
619 Chang Y-H, Hwan Shin J, Choi S-H, Kang J, Choi Y, Park H-S, Kim H, Kook
620 J-K. 2013. Draft Genome Sequence of *Fusobacterium nucleatum* subsp.
621 *nucleatum* ChDC F316, Isolated from a Human Peri-implantitis Lesion in the
622 Republic of Korea. *Genome Announc* 1:e01041-01013.
- 623 20. Lynch MC, Kuramitsu HK. 1999. Role of Superoxide Dismutase Activity in the
624 Physiology of *Porphyromonas gingivalis*. *Infect Immun* 67:3367-3375.

- 625 21. Nguyen PT, Abranches J, Phan TN, Marquis RE. 2002. Repressed respiration
626 of oral streptococci grown in biofilms. *Curr Microbiol* 44:262-266.
- 627 22. Poyart C, Quesne G, Coulon S, Berche P, Trieu-Cuot P. 1998. Identification
628 of Streptococci to Species Level by Sequencing the Gene Encoding the
629 Manganese-Dependent Superoxide Dismutase. *J Clin Microbiol* 36:41-47.
- 630 23. Sharma A, Sharma S. 2011. Reactive Oxygen Species and Antioxidants in
631 Periodontics: A Review, *Int J Dent Clin* 3(2):44-47.
- 632 24. Chapple IL. 1996. Role of free radicals and antioxidants in the pathogenesis
633 of the inflammatory periodontal diseases. *Clin Mol Pathol* 49:M247-255.
- 634 25. Dix TA, Aikens J. 1993. Mechanisms and biological relevance of lipid
635 peroxidation initiation. *Chem Res Toxicol* 6:2-18.
- 636 26. Dix TA, Hess KM, Medina MA, Sullivan RW, Tilly SL, Webb TL. 1996.
637 Mechanism of site-selective DNA nicking by the hydrodioxyl (perhydroxyl)
638 radical. *Biochemistry* 35:4578-4583.
- 639 27. Waddington RJ, Moseley R, Embery G. 2000. Reactive oxygen species: a
640 potential role in the pathogenesis of periodontal diseases. *Oral Dis* 6:138-151.
- 641 28. Dahiya P, Kamal R, Gupta R, Bhardwaj R, Chaudhary K, Kaur S. 2013.
642 Reactive oxygen species in periodontitis. *J Indian Soc Periodontol* 17:411-
643 416.
- 644 29. Chapple IL, Brock GR, Milward MR, Ling N, Matthews JB. 2007.
645 Compromised GCF total antioxidant capacity in periodontitis: cause or effect?
646 *J Clin Periodontol* 34:103-110.
- 647 30. Ling MR, Chapple IL, Matthews JB. 2015. Peripheral blood neutrophil
648 cytokine hyper-reactivity in chronic periodontitis. *Innate Immun* 21:714-725.

- 649 31. Barrientos L, Marin-Esteban V, de Chaisemartin L, Le-Moal VL, Sandre C,
650 Bianchini E, Nicolas V, Pallardy M, Chollet-Martin S. 2013. An improved
651 strategy to recover large fragments of functional human neutrophil
652 extracellular traps. *Front Immunol* 4:166.
- 653 32. Halverson TW, Wilton M, Poon KK, Petri B, Lewenza S. 2015. DNA is an
654 antimicrobial component of neutrophil extracellular traps. *PLoS Pathog*
655 11:e1004593.
- 656 33. Vitkov L, Klappacher M, Hannig M, Krautgartner WD. 2009. Extracellular
657 neutrophil traps in periodontitis. *J Periodontal Res* 44:664-672.
- 658 34. Vitkov L, Klappacher M, Hannig M, Krautgartner WD. 2010. Neutrophil fate in
659 gingival crevicular fluid. *Ultrastruct Pathol* 34:25-30.
- 660 35. Whitchurch CB, Tolker-Nielsen T, Ragas PC, Mattick JS. 2002. Extracellular
661 DNA required for bacterial biofilm formation. *Science* 295:1487.
- 662 36. Palmer LJ, Chapple IL, Wright HJ, Roberts A, Cooper PR. 2012. Extracellular
663 deoxyribonuclease production by periodontal bacteria. *J Periodontal Res*
664 47:439-445.
- 665 37. Brinkmann V, Zychlinsky A. 2012. Neutrophil extracellular traps: is immunity
666 the second function of chromatin? *J Cell Biol* 198:773-783.
- 667 38. Menegazzi R, Decleva E, Dri P. 2012. Killing by neutrophil extracellular traps:
668 fact or folklore? *Blood* 119:1214-1216.
- 669 39. MacLean-Fletcher S, Pollard TD. 1980. Mechanism of action of cytochalasin
670 B on actin. *Cell* 20:329-341.
- 671 40. Neeli I, Dwivedi N, Khan S, Radic M. 2009. Regulation of extracellular
672 chromatin release from neutrophils. *J Innate Immun* 1:194-201.

- 673 41. Sumida GM, Yamada S. 2015. Rho GTPases and the Downstream Effectors
674 Actin-related Protein 2/3 (Arp2/3) Complex and Myosin II Induce Membrane
675 Fusion at Self-contacts. *J Biol Chem* 290:3238-3247.
- 676 42. de Oliveira CA, Mantovani B. 1988. Latrunculin A is a potent inhibitor of
677 phagocytosis by macrophages. *Life Sci* 43:1825-1830.
- 678 43. Palmer LJ, Cooper PR, Ling MR, Wright HJ, Huissoon A, Chapple IL. 2012.
679 Hypochlorous acid regulates neutrophil extracellular trap release in humans.
680 *Clin Exp Immunol* 167:261-268.
- 681 44. Kirchner T, Hermann E, Möller S, Klinger M, Solbach W, Laskay T, Behnen
682 M. 2013. Flavonoids and 5-Aminosalicylic Acid Inhibit the Formation of
683 Neutrophil Extracellular Traps. *Mediators Inflamm* 2013:710239.
- 684 45. Kirchner T, Möller S, Klinger M, Solbach W, Laskay T, Behnen M. 2012. The
685 Impact of Various Reactive Oxygen Species on the Formation of Neutrophil
686 Extracellular Traps. *Mediators Inflamm* 2012:849136.
- 687 46. Uriarte SM, Edmisson JS, Jimenez-Flores E. 2016. Human neutrophils and
688 oral microbiota: a constant tug-of-war between a harmonious and a discordant
689 coexistence. *Immunol Rev* 273:282-298.
- 690 47. Pilsczek FH, Salina D, Poon KK, Fahey C, Yipp BG, Sibley CD, Robbins SM,
691 Green FH, Surette MG, Sugai M, Bowden MG, Hussain M, Zhang K, Kubes P.
692 2010. A novel mechanism of rapid nuclear neutrophil extracellular trap
693 formation in response to *Staphylococcus aureus*. *J Immunol* 185:7413-7425.
- 694 48. Sabroe I, Dower SK, Whyte MK. 2005. The role of Toll-like receptors in the
695 regulation of neutrophil migration, activation, and apoptosis. *Clin Infect Dis* 41
696 Suppl 7:S421-426.

- 697 49. Gould TJ, Vu TT, Swystun LL, Dwivedi DJ, Mai SH, Weitz JI, Liaw PC. 2014.
698 Neutrophil extracellular traps promote thrombin generation through platelet-
699 dependent and platelet-independent mechanisms. *Arterioscler Thromb Vasc*
700 *Biol* 34:1977-1984.
- 701 50. Hayashi F, Means TK, Luster AD. 2003. Toll-like receptors stimulate human
702 neutrophil function. *Blood* 102:2660-2669.
- 703 51. Salmon D, Verdier F, Malhotra K, Pussard E, Clavier F, Le Bras J, Vilde JL,
704 Pocidalo JJ. 1990. Absence of effect of chloroquine in vivo on neutrophil
705 oxidative metabolism in human subjects. *J Antimicrob Chemother* 25(3):367-
706 70.
- 707 52. Graham LM, Gupta V, Schafer G, Reid DM, Kimberg M, Dennehy KM,
708 Hornsell WG, Guler R, Campanero-Rhodes MA, Palma AS, Feizi T, Kim SK,
709 Sobieszczuk P, Willment JA, Brown GD. 2012. The C-type lectin receptor
710 CLECSF8 (CLEC4D) is expressed by myeloid cells and triggers cellular
711 activation through Syk kinase. *J Biol Chem* 287:25964-25974.
- 712 53. Ekman A-K, Cardell LO. 2010. The expression and function of Nod-like
713 receptors in neutrophils. *Immunology* 130:55-63.
- 714 54. Farhat K, Riekenberg S, Heine H, Debarry J, Lang R, Mages J, Buwitt-
715 Beckmann U, Röschmann K, Jung G, Wiesmüller K-H, Ulmer AJ. 2008.
716 Heterodimerization of TLR2 with TLR1 or TLR6 expands the ligand spectrum
717 but does not lead to differential signaling. *J Leukoc Biol* 83(3):692-701.
- 718 55. Labro MT, Babin-Chevaye C. 1988. Effects of amodiaquine, chloroquine, and
719 mefloquine on human polymorphonuclear neutrophil function in vitro.
720 *Antimicrob Agents Chemother* 32:1124-1130.

- 721 56. Al-Bari MA. 2015. Chloroquine analogues in drug discovery: new directions of
722 uses, mechanisms of actions and toxic manifestations from malaria to
723 multifarious diseases. *J Antimicrob Chemother* 70:1608-1621.
- 724 57. Rouhanizadeh M, Hwang J, Clempus RE, Marcu L, Lassegue B, Sevanian A,
725 Hsiai TK. 2005. Oxidized-1-palmitoyl-2-arachidonoyl-sn-glycero-3-
726 phosphorylcholine induces vascular endothelial superoxide production:
727 implication of NADPH oxidase. *Free Radic Biol Med* 39:1512-1522.
- 728 58. Starosta V, Wu T, Zimman A, Pham D, Tian X, Oskolkova O, Bochkov V,
729 Berliner JA, Birukova AA, Birukov KG. 2012. Differential Regulation of
730 Endothelial Cell Permeability by High and Low Doses of Oxidized 1-Palmitoyl-
731 2-Arachidonoyl-sn-Glycero-3-Phosphocholine. *Am J Respir Cell Mol Biol*
732 46:331-341.
- 733 59. Joshi T, Butchar JP, Tridandapani S. 2006. Fcγ receptor signaling in
734 phagocytes. *Int J Hematol* 84:210-216.
- 735 60. Lebeaux D, Chauhan A, Rendueles O, Beloin C. 2013. From in vitro to in vivo
736 Models of Bacterial Biofilm-Related Infections. *Pathogens* 2:288-356.
- 737 61. Matsuura Y, Takehira M, Joti Y, Ogasahara K, Tanaka T, Ono N, Kunishima
738 N, Yutani K. 2015. Thermodynamics of protein denaturation at temperatures
739 over 100 °C: CutA1 mutant proteins substituted with hydrophobic and charged
740 residues. *Sci Rep* 5:15545.
- 741 62. Hirschfeld J, Roberts HM, Chapple IL, Parcina M, Jepsen S, Johansson A,
742 Claesson R. 2016. Effects of *Aggregatibacter actinomycetemcomitans*
743 leukotoxin on neutrophil migration and extracellular trap formation. *J Oral*
744 *Microbiol* 8:33070.

- 745 63. White P, Sakellari D, Roberts H, Risafi I, Ling M, Cooper P, Milward M,
746 Chapple I. 2016. Peripheral blood neutrophil extracellular trap production and
747 degradation in chronic periodontitis. *J Clin Periodontol* 43:1041-1049.
- 748 64. Ling MR, Chapple IL, Matthews JB. 2016. Neutrophil superoxide release and
749 plasma C-reactive protein levels pre- and post-periodontal therapy. *J Clin*
750 *Periodontol* 43:652-658.
- 751 65. Scott DA, Krauss JL. 2012. Neutrophils in periodontal inflammation. *Front*
752 *Oral Biol* 15:56-83.
- 753 66. Hirschfeld J, Kawai T. 2015. Oral inflammation and bacteremia: implications
754 for chronic and acute systemic diseases involving major organs. *Cardiovasc*
755 *Hematol Disord Drug Targets* 15:70-84.
- 756 67. Roberts H, White P, Dias I, McKaig S, Veeramachaneni R, Thakker N, Grant
757 M, Chapple I. 2016. Characterization of neutrophil function in Papillon-Lefevre
758 syndrome. *J Leukoc Biol* 100:433-444.
- 759 68. Persson S, Edlund MB, Claesson R, Carlsson J. 1990. The formation of
760 hydrogen sulfide and methyl mercaptan by oral bacteria. *Oral Microbiol*
761 *Immunol* 5:195-201.
- 762 69. Gerencser MA, Slack JM. 1969. Identification of Human Strains of
763 *Actinomyces viscosus*. *Appl Microbiol* 18:80-87.
- 764 70. White PC. 2016. The role of neutrophil extracellular traps in the pathogenesis
765 of periodontal diseases. Ph.D. University of Birmingham.
- 766 71. White PC, Chicca IJ, Ling MR, Wright HJ, Cooper PR, Milward MR, Chapple
767 IL. 2017. Characterization, Quantification, and Visualization of Neutrophil
768 Extracellular Traps. *Methods Mol Biol* 1537:481-497.

769 72. Malawista SE, Gee JB, Bensch KG. 1971. Cytochalasin B reversibly inhibits
770 phagocytosis: functional, metabolic, and ultrastructural effects in human blood
771 leukocytes and rabbit alveolar macrophages. Yale J Biol Med 44:286-300.

772

773

774

775

776

777

778

779

780

781

782

783

784

785

786

787

788

789

790

791

792

793

794 **FIGURE LEGENDS**

795

796 **Figure 1**

797 **Neutrophil ROS production in response to periodontal bacteria.** Neutrophil total
798 reactive oxygen species (ROS) (**A**), extracellular ROS (**B**) and superoxide production
799 (**C**) were quantified and time-course production assayed over 130 min in response to
800 periodontal bacteria using luminol, isoluminol and lucigenin enhanced
801 chemiluminescence, respectively. ROS release in response to PBS (unstimulated
802 negative control), phorbol 12-myristate 13-acetate (PMA) (25 nM, positive control)
803 and opsonised *S. aureus* (positive control) was also quantified. Data are presented
804 as relative light units (RLU) and represent neutrophils of five different donors
805 assessed in triplicate wells.

806

807 **Figure 2**

808 **Quantification of NET production in response to periodontal bacteria.**
809 Neutrophil extracellular trap (NET) production was quantified in response to
810 periodontal bacteria and to PBS (unstimulated negative control), phorbol 12-
811 myristate 13-acetate (PMA) (50 nM, positive control) and opsonised *S. aureus*
812 (positive control). NET-DNA was quantified using Sytox Green assay (**A**) and NET-
813 bound neutrophil elastase (**B**), myeloperoxidase (**C**) and cathepsin G (**D**) were
814 quantified colorimetrically. Data are presented as arbitrary fluorescence units (AFU),
815 U/mL or mU/mL and represent neutrophils of ten different donors assessed in
816 triplicate wells.

817

818 **Figure 3**

819 **NET entrapment of periodontal bacteria. A:** Neutrophil extracellular trap (NET)
820 entrapment of bacteria that were not assigned to a Socransky complex (white, grey,
821 black), as well as purple, yellow, green, orange, red and blue complex bacteria.
822 Results are normalised to fluorescein isothiocyanate-stained bacteria in PBS.
823 Statistical significance of bacterial entrapment in NETs is shown relative to bacteria
824 entrapped by unstimulated neutrophils and degraded NETs (n.s.=not significant).
825 Data are presented as arbitrary fluorescence units (AFU) **B:** Representative images
826 of bacterial entrapment by NETs. Neutrophils (yellow arrows) incubated with PBS
827 (control), live *A. actinomycetemcomitans* serotype a, *V. parvula* or *A. viscosus* were
828 visualised by scanning electron microscopy. Blue arrows indicate NET strand
829 structures and NET-associated bacteria are indicated with green arrows.
830 Representative images of three experiments are shown, the scale bar represents
831 10µm. **C:** Bacterial survival after exposure to neutrophils, NETs, degraded NETs and
832 neutrophils with cytochalasin B (n.s.=not significant). All results shown represent
833 neutrophils of five different donors assessed in triplicate wells.

834

835 **Figure 4**

836 **Effect of NADPH-oxidase pathway modulating agents on ROS and NET**

837 **production.** Total reactive oxygen species (ROS) (**A**) and Neutrophil extracellular
838 trap (NET) (**B**) production by neutrophils was quantified in response to selected
839 periodontal bacteria, as well as to phorbol 12-myristate 13-acetate (PMA) (50 nM)
840 and opsonised *S. aureus* (positive controls) following pre-incubation (30 mins) with
841 diphenyleneiodonium (DPI) (25 µM), N-acetyl-cysteine (NAC) (10 mM) and taurine
842 (100 mM). Data are presented as relative light units (RLU) and arbitrary fluorescence
843 units (AFU). Experiments were conducted in duplicate using three different donors.

844
845
846
847
848
849
850
851
852
853
854
855
856
857
858
859
860
861
862
863
864
865
866
867
868

Figure 5

Effect of Toll-like receptor inhibition on ROS and NET production. Total reactive oxygen species (ROS) (**A**) and Neutrophil extracellular trap (NET) (**B**) production by neutrophils was quantified in response to selected periodontal bacteria, as well as to phorbol 12-myristate 13-acetate (PMA) (50 nM) and opsonised *S. aureus* (positive controls) following pre-incubation (30 mins) with chloroquine (100 µM), oxidised 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine (OxPAPC) (30 µg/mL) or chloroquine and OxPAPC. Experiments were conducted in duplicate wells using three different donors (n.s.=not significant).

869 **Table 1**

870 Bacteria used, their assignment to Socransky complexes and growth conditions.



Bacterial strain	ATCC number	Socransky complex	Growth conditions
<i>Actinomyces viscosus</i> (naeslundii genospecies 2)	43146	blue	anaerobic
<i>Aggregatibacter actinomycetemcomitans</i> serotype a	29523	green	anaerobic
<i>Aggregatibacter actinomycetemcomitans</i> serotype b	43718	white	anaerobic
<i>Campylobacter rectus</i>	33238(371)	orange	anaerobic
<i>Campylobacter showae</i>	51146	orange	anaerobic
<i>Capnocytophaga gingivalis</i>	33624(27)	green	anaerobic
<i>Capnocytophaga sputigena</i>	33612(4)	green	anaerobic
<i>Fusobacterium nucleatum</i> subsp. nucleatum	25586	orange	anaerobic
<i>Fusobacterium nucleatum</i> subsp. polymorphum	10953	orange	anaerobic
<i>Porphyromonas gingivalis</i>	W83	red	anaerobic
<i>Propionibacterium acnes</i>	11827	white	anaerobic
<i>Selenomonas noxia</i>	43541	white	anaerobic
<i>Staphylococcus aureus</i> (opsonised)	9144	N/A	aerobic
<i>Streptococcus anginosus</i>	33397	yellow	5% CO ₂
<i>Streptococcus constellatus</i>	27823(M32b)	orange	5% CO ₂
<i>Streptococcus gordonii</i>	10558	yellow	5% CO ₂
<i>Streptococcus intermedius</i>	27335	yellow	5% CO ₂
<i>Streptococcus oralis</i>	35037	yellow	5% CO ₂
<i>Streptococcus sanguinis</i>	10556	yellow	5% CO ₂
<i>Veillonella parvula</i>	10790	purple	anaerobic

872

Figure 1



A

Total ROS (luminol)





B

Extracellular ROS (isoluminol)



C

Superoxide (lucigenin)



- PBS
- PMA
- F. nucleatum n.
- V. parvula
- A. viscosus
- S. sanguinis
- S. constellatus
- A. actinomyc. a
- C. gingivalis
- S. gordonii
- A. actinomyc. b
- S. intermedius
- C. rectus
- F. nucleatum p.
- Ops. S. aureus
- C. sputigena
- S. anginosus
- P. acnes
- S. noxia
- C. showae
- S. oralis
- P. gingivalis

Figure 2




Figure 3





Figure 4

A



B





Figure 5

A



B

